US Patent

US10328029 — Pharmaceutical composition

Method of Use · Assigned to Cycle Pharmaceuticals Ltd · Expires 2035-01-05 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral pharmaceutical compositions containing nitisinone or a pharmaceutically acceptable salt thereof for treating tyrosinemia and alkaptonuria.

USPTO Abstract

The present invention relates to oral pharmaceutical compositions comprising nitisinone, or a pharmaceutically acceptable salt thereof, their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria. The compositions have improved stability characteristics. The invention also relates to processes for producing nitisinone.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1836 — nitisinone
U-1836 — nitisinone
U-1836 — nitisinone

Patent Metadata

Patent number
US10328029
Jurisdiction
US
Classification
Method of Use
Expires
2035-01-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Cycle Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.